iPSC-MSC Exosome Composition for Non-Alcoholic Steatohepatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for non-alcoholic steatohepatitis are not safe and long-term effective, and there is a need for a novel therapeutic composition that can effectively treat this chronic disease.
Innovation Solution
A pharmaceutical composition comprising exosomes isolated from induced pluripotent stem cell-derived mesenchymal stem cells, which may or may not be pretreated with a material, is developed to treat non-alcoholic steatohepatitis, leveraging their excellent prophylactic and therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents for obesity, insulin tolerance, or hyperlipidemia are used to treat non-alcoholic steatohepatitis, then symptom improvement is achieved, but long-term safety is compromised due to side effects
Solution Approach 1:
The patent extracts and utilizes exosomes from induced pluripotent stem cell-derived mesenchymal stem cells as the active therapeutic component, separating the beneficial therapeutic effects from the harmful side effects of conventional medications. This extraction approach provides a safer alternative while maintaining treatment effectiveness.
Solution Approach 2:
The patent employs exosomes as an intermediary substance that mediates the therapeutic effect between the stem cells and the target tissues. These exosomes carry bioactive molecules that exert protective effects on liver cells without the harmful side effects of conventional drugs, serving as a safe intermediate therapeutic agent.
2Quantity of substance
If only a small amount of exosomes is obtained from mesenchymal stem cells, then the simplicity of obtaining exosomes is maintained, but the quantity required for commercial availability is insufficient
Solution Approach 1:
The patent utilizes induced pluripotent stem cells that can differentiate into mesenchymal stem cells, which in turn secrete exosomes with multiple therapeutic functions. This multi-functional cell system allows for both high-volume exosome production and diverse therapeutic applications, addressing both quantity and productivity requirements.
Solution Approach 2:
The patent performs preliminary differentiation of induced pluripotent stem cells into mesenchymal stem cell progenitors before exosome extraction. This preliminary action enhances the exosome-producing capacity of the cells, thereby increasing the quantity and productivity of exosome generation for commercial purposes.
3Reliability
If mesenchymal stem cells are used directly for therapy, then the therapeutic effect is achieved, but the proliferative ability decreases with repetition of passages
Solution Approach 1:
The patent extracts exosomes from mesenchymal stem cells rather than using the cells themselves for therapy. This extraction approach allows repeated harvesting of exosomes from a single cell population without the loss of cellular functionality or proliferative ability that occurs with repeated cell passaging.
Solution Approach 2:
The patent uses exosomes as copies or carriers of the therapeutic information and bioactive molecules from mesenchymal stem cells. These exosome copies can be produced and administered multiple times without depleting or deteriorating the original stem cell population, maintaining both reliability and duration of action.
Data Source
AI summary
The present disclosure relates to a pharmaceutical composition for prevention or treatment of non-alcoholic steatohepatitis, the composition comprising, as an active ingredient, exosomes isolated from induced pluripotent stem cell-derived mesenchymal stem cells which have been or have not been treated with a pretreatment material. The exosomes of the present disclosure exhibit a more improved effect of preventing or treating non-alcoholic steatohepatitis, compared to those isolated from conventional mesenchymal stem cells and as such, can be advantageously used for relevant research and development, and productization.